Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF-Reference-Cited by-同舟云学术

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF

Published:2020-09-15 Issue:11 Volume:22 Page:2147-2156
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

McEwan Phil¹,Darlington Oliver¹,McMurray John J.V.²,Jhund Pardeep S.²,Docherty Kieran F.²,Böhm Michael³,Petrie Mark C.²,Bergenheim Klas⁴,Qin Lei⁵

Affiliation:

1. Health Economics and Outcomes Research Ltd Cardiff UK

2. British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK

3. Department of Medicine Saarland University Hospital Homburg/Saar Germany

4. AstraZeneca, CVRM Biopharmaceutical Gothenburg Sweden

5. AstraZeneca, CVRM Biopharmaceutical Gaithersburg MD USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1978

Reference49 articles.

1. Global Public Health Burden of Heart Failure

2. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)

3. The Global Health and Economic Burden of Hospitalizations for Heart Failure

4. Rehospitalization for Heart Failure

5. What are the costs of heart failure?

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System;Clinical Therapeutics;2024-09

2. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF;JACC: Heart Failure;2024-09

3. Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy;JACC: Heart Failure;2024-08

4. Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice;Revista Portuguesa de Cardiologia;2024-07

5. The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure;Journal of Clinical Medicine;2024-05-29